Immuno-Oncology Brings Forth Promises and Challenges

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology
September 30, 2014 – 
The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.
Segment 10 - Paying for Combination Therapies
September 30, 2014 – 
Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.
Segment 9 - Safety Concerns with Oncolytic Virus Therapies
September 30, 2014 – 
Although the oncolytic virus therapy being used in the OPTIM trial has been modified in a way that there should be minimal safety concerns, it should still be handled in a way to limit adverse effects and mutations, according to Kimberly Shafer-Weaver, PhD.
Segment 8 - Overall Survival and Ongoing Combination Clinical Trials
September 30, 2014 – 
While it would be nice to think that one and only one therapy would be effective at combatting cancer, combination therapy is needed, Kimberly Shafer-Weaver, PhD, said.
Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology
September 30, 2014 – 
People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.
Segment 6 - Including Patient-Reported Outcomes
September 30, 2014 – 
Although there are some efforts to marry progression-free survival benefits to clinical benefits defined by the patients, the approach is still in the early stages and needs to be moved forward more quickly, according to Michael Kolodziej, MD.
Segment 5 - Establishing the Value of Immunotherapy in Oncology
September 30, 2014 – 
Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
Segment 4 - From Animal Models to Human Bodies
September 30, 2014 – 
Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.
Segment 3 - Pairing Patients with the Right Therapies
September 30, 2014 – 
In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.
Segment 2 - Bringing Latest Innovations to the Public
September 30, 2014 – 
Jianda Yuan, MD, PhD, explains the importance of bringing the latest innovations to the public and how more data are showing promising immunologic and clinical responses for different types of cancer.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.